Elevation Oncology today announced plans to expand its ongoing Phase 1 clinical trial to include two combination cohorts evaluating EO-3021 for the treatment of advanced gastric or gastroesophageal junction cancer. Following recently signed clinical supply agreements with Eli Lilly and Company and GSK, Elevation Oncology will evaluate EO-3021 in combination with ramucirumab and dostarlimab, respectively. "We are excited to begin evaluating EO-3021 together with ramucirumab, a VEGFR2 inhibitor, and with dostarlimab, a PD-1 inhibitor, in the second- and first-line settings, respectively,” said Valerie Malyvanh Jansen, M.D., Ph.D., Chief Medical Officer of Elevation Oncology. Full release at https://lnkd.in/eMFCWzhu
Exciting progress. Congrats and continued success!
Senior Medical doctor @ CK Birla Hospitals | Clinical Research & Drug Safety
1wCommenting for better reach Respected sir / Mentor 🙏🏻 I want to draw your kind attention, i am interested to do *medical writing and review journals, proofreading , doing pharmacovigilance, research writing, Tableau statistics, R software trained professional, article writing content writing, abstract and dissertation writing and reviewing clinical research documents*. Extensive experience in clinical research and healthcare management in analytical and research skills. Thanking you in anticipation, Regards, Dr Priyam Upadhyay [email protected] 9318395789